› Forums › General Melanoma Community › Has anyone done PD-1 or PDL-1 not sure of spelling
- This topic has 21 replies, 3 voices, and was last updated 14 years, 2 months ago by
killmel.
- Post
-
- October 4, 2011 at 9:45 pm
I am suppose to have Yervoy soon , Ipi, and I keep hearing about this trial called PD-1 or PDL-1. I’ve had quite a Few
People from the bulletin board tell me to hold off on Ipi and try to get into this other trial. So now I’m totally confused. Can anyone share their knowledge on this and if you are in
The trial and what the side effects are like. Sometimes it’s more stressful trying to figure out what treatment to do than having cancer itself. Everyone wants to tell you what to do and where to go.Becky Stage IV
I am suppose to have Yervoy soon , Ipi, and I keep hearing about this trial called PD-1 or PDL-1. I’ve had quite a Few
People from the bulletin board tell me to hold off on Ipi and try to get into this other trial. So now I’m totally confused. Can anyone share their knowledge on this and if you are in
The trial and what the side effects are like. Sometimes it’s more stressful trying to figure out what treatment to do than having cancer itself. Everyone wants to tell you what to do and where to go.Becky Stage IV
- Replies
-
-
- October 4, 2011 at 10:15 pm
alan kravitz says:
June 11, 2011 at 3:25 pmI am a survivor of Stage IV Metastatic Melanoma after two years in the Phase 1B TRIAL of anti Pd-1/MDX-1106. I completed my treatments in August of 2010 and remain NED. I am interested in organizing other survivors to launch a serious advocacy effort on the part of. survivors. I have posted my thoughts on the Forums of the Melanoma International Foundation and several other locations. The effort would be modeled on those that targeted HIV and AIDS. If interested, contact me directly at Alankravitz@aol.com.
Lynn Luckeroth says:
I did two 12 week trials (every other week) with MDX 1106 and 6 peptides titled” Phase I Study of Anti-PD-1 Human Monoclonal Antibody MDX-1106 and Vaccine Therapy Comprising gp100:209-217(210M) Peptide, MART-1:26-35(27L) Peptide, gp100:280-288(288V) Peptide, NY-ESO-1 Peptide, and Montanide ISA 51 VG in Patients With Resected Stage IV Melanoma ”
I am now receiving booster IV’s of MDX 1106 every 3 months- having my firt booster on June 8th, 2011. I am stage 4 melanoma NED since March 26, 2010 ( 15 months)
best regards,
Jimmy B
-
- October 4, 2011 at 10:15 pm
alan kravitz says:
I am a survivor of Stage IV Metastatic Melanoma after two years in the Phase 1B TRIAL of anti Pd-1/MDX-1106. I completed my treatments in August of 2010 and remain NED. I am interested in organizing other survivors to launch a serious advocacy effort on the part of. survivors. I have posted my thoughts on the Forums of the Melanoma International Foundation and several other locations. The effort would be modeled on those that targeted HIV and AIDS. If interested, contact me directly at Alankravitz@aol.com.
Lynn Luckeroth says:
I did two 12 week trials (every other week) with MDX 1106 and 6 peptides titled” Phase I Study of Anti-PD-1 Human Monoclonal Antibody MDX-1106 and Vaccine Therapy Comprising gp100:209-217(210M) Peptide, MART-1:26-35(27L) Peptide, gp100:280-288(288V) Peptide, NY-ESO-1 Peptide, and Montanide ISA 51 VG in Patients With Resected Stage IV Melanoma ”
I am now receiving booster IV’s of MDX 1106 every 3 months- having my firt booster on June 8th, 2011. I am stage 4 melanoma NED since March 26, 2010 ( 15 months)
best regards,
Jimmy B
-
- October 4, 2011 at 10:15 pm
alan kravitz says:
I am a survivor of Stage IV Metastatic Melanoma after two years in the Phase 1B TRIAL of anti Pd-1/MDX-1106. I completed my treatments in August of 2010 and remain NED. I am interested in organizing other survivors to launch a serious advocacy effort on the part of. survivors. I have posted my thoughts on the Forums of the Melanoma International Foundation and several other locations. The effort would be modeled on those that targeted HIV and AIDS. If interested, contact me directly at Alankravitz@aol.com.
Lynn Luckeroth says:
I did two 12 week trials (every other week) with MDX 1106 and 6 peptides titled” Phase I Study of Anti-PD-1 Human Monoclonal Antibody MDX-1106 and Vaccine Therapy Comprising gp100:209-217(210M) Peptide, MART-1:26-35(27L) Peptide, gp100:280-288(288V) Peptide, NY-ESO-1 Peptide, and Montanide ISA 51 VG in Patients With Resected Stage IV Melanoma ”
I am now receiving booster IV’s of MDX 1106 every 3 months- having my firt booster on June 8th, 2011. I am stage 4 melanoma NED since March 26, 2010 ( 15 months)
best regards,
Jimmy B
-
- October 5, 2011 at 12:49 am
Hi Becky,
I have no experience with PD1.
I would recommend you contact your doctor ASAP who prescribed IPI and get his opinion before you go through all the hassles of get insurance approvals, etc.
Your doctor is the best person to explain PD1 to you.
-
- October 5, 2011 at 12:49 am
Hi Becky,
I have no experience with PD1.
I would recommend you contact your doctor ASAP who prescribed IPI and get his opinion before you go through all the hassles of get insurance approvals, etc.
Your doctor is the best person to explain PD1 to you.
-
- October 5, 2011 at 12:49 am
Hi Becky,
I have no experience with PD1.
I would recommend you contact your doctor ASAP who prescribed IPI and get his opinion before you go through all the hassles of get insurance approvals, etc.
Your doctor is the best person to explain PD1 to you.
-
- October 5, 2011 at 1:33 am
Becky,
Other patients are trying to tell you that if you do Ipi (Yervoy) first, and doesn't produce an immune response, then it may disqualify you from doing PD-1 or PD-L1 therapies.
Each trial have their own exclusion criteria. If you think you might want to do PD-1 therapy, you have to do it before Ipi. Ipi is now a FDA approved Drug here in the States. PD-1 on the other hand is still in clinical trials.
Example of exclusion criteria for a PD-1 trial
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T-cell costimulation pathways)
What I am trying to say is choose your therapy wisely.
-
- October 5, 2011 at 2:24 am
Everyone is talking about this PD1 and PDL1….however, the trials aren't everywhere , so you'd have to travel. Heck, I live in Pittsburgh, and go to the Hillman Center, which I was told is one of the top cancer centers, and I can't even find a listing for a trial here for it, so I don't know how everyone is supposed to try to get into it!
I am going to ask my doctor about it when I see him next Friday, just to find out more information from them.
I just hope it becomes an actual FDA approved treatment sometime soon, so ALL OF US can have the benefit of using it. I hope no red tape, or government garbage will end up holding it up somewhere along the line for those of us who greatly need these treatments.
-
- October 5, 2011 at 12:22 pm
momod2kids,
I also went to the Hillman Center and actually Dr. Kirkwood is still my Oncologist.
Anti-PD-1 and PD-L1 are relativley new to come to clinical trials. The location are mainly on east coast. Yale, Sloan Kettering, John Hopkins, Moffit Center in Flordia. A new study is just recruiting with another version of PD-1 called AMP-224. Trial Lcations are as Follow:
LocationsUnited States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Erica Brennan 313-576-9816 brennane@karmanos.org Contact: Karen Forman 313-576-8096 formank@karmanos.org Principal Investigator: Patricia LoRusso, DO United States, North Carolina Carolina BioOncology Institute Recruiting Huntersville, North Carolina, United States, 28078 Contact: Jahleen Byers 704-947-6599 jbyers@carolinabiooncology.org Principal Investigator: John Powderly, MD United States, Tennessee Sarah Cannon Research Institute Recruiting Nashville, Tennessee, United States, 37203 Contact: Patient Referral Line 615-339-4214 Principal Investigator: Jeffrey Infante, MD Best regards,
Jimmy B
-
- October 5, 2011 at 12:22 pm
momod2kids,
I also went to the Hillman Center and actually Dr. Kirkwood is still my Oncologist.
Anti-PD-1 and PD-L1 are relativley new to come to clinical trials. The location are mainly on east coast. Yale, Sloan Kettering, John Hopkins, Moffit Center in Flordia. A new study is just recruiting with another version of PD-1 called AMP-224. Trial Lcations are as Follow:
LocationsUnited States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Erica Brennan 313-576-9816 brennane@karmanos.org Contact: Karen Forman 313-576-8096 formank@karmanos.org Principal Investigator: Patricia LoRusso, DO United States, North Carolina Carolina BioOncology Institute Recruiting Huntersville, North Carolina, United States, 28078 Contact: Jahleen Byers 704-947-6599 jbyers@carolinabiooncology.org Principal Investigator: John Powderly, MD United States, Tennessee Sarah Cannon Research Institute Recruiting Nashville, Tennessee, United States, 37203 Contact: Patient Referral Line 615-339-4214 Principal Investigator: Jeffrey Infante, MD Best regards,
Jimmy B
-
- October 5, 2011 at 12:22 pm
momod2kids,
I also went to the Hillman Center and actually Dr. Kirkwood is still my Oncologist.
Anti-PD-1 and PD-L1 are relativley new to come to clinical trials. The location are mainly on east coast. Yale, Sloan Kettering, John Hopkins, Moffit Center in Flordia. A new study is just recruiting with another version of PD-1 called AMP-224. Trial Lcations are as Follow:
LocationsUnited States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Erica Brennan 313-576-9816 brennane@karmanos.org Contact: Karen Forman 313-576-8096 formank@karmanos.org Principal Investigator: Patricia LoRusso, DO United States, North Carolina Carolina BioOncology Institute Recruiting Huntersville, North Carolina, United States, 28078 Contact: Jahleen Byers 704-947-6599 jbyers@carolinabiooncology.org Principal Investigator: John Powderly, MD United States, Tennessee Sarah Cannon Research Institute Recruiting Nashville, Tennessee, United States, 37203 Contact: Patient Referral Line 615-339-4214 Principal Investigator: Jeffrey Infante, MD Best regards,
Jimmy B
-
- October 5, 2011 at 2:24 am
Everyone is talking about this PD1 and PDL1….however, the trials aren't everywhere , so you'd have to travel. Heck, I live in Pittsburgh, and go to the Hillman Center, which I was told is one of the top cancer centers, and I can't even find a listing for a trial here for it, so I don't know how everyone is supposed to try to get into it!
I am going to ask my doctor about it when I see him next Friday, just to find out more information from them.
I just hope it becomes an actual FDA approved treatment sometime soon, so ALL OF US can have the benefit of using it. I hope no red tape, or government garbage will end up holding it up somewhere along the line for those of us who greatly need these treatments.
-
- October 5, 2011 at 2:24 am
Everyone is talking about this PD1 and PDL1….however, the trials aren't everywhere , so you'd have to travel. Heck, I live in Pittsburgh, and go to the Hillman Center, which I was told is one of the top cancer centers, and I can't even find a listing for a trial here for it, so I don't know how everyone is supposed to try to get into it!
I am going to ask my doctor about it when I see him next Friday, just to find out more information from them.
I just hope it becomes an actual FDA approved treatment sometime soon, so ALL OF US can have the benefit of using it. I hope no red tape, or government garbage will end up holding it up somewhere along the line for those of us who greatly need these treatments.
-
- October 5, 2011 at 1:33 am
Becky,
Other patients are trying to tell you that if you do Ipi (Yervoy) first, and doesn't produce an immune response, then it may disqualify you from doing PD-1 or PD-L1 therapies.
Each trial have their own exclusion criteria. If you think you might want to do PD-1 therapy, you have to do it before Ipi. Ipi is now a FDA approved Drug here in the States. PD-1 on the other hand is still in clinical trials.
Example of exclusion criteria for a PD-1 trial
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T-cell costimulation pathways)
What I am trying to say is choose your therapy wisely.
-
- October 5, 2011 at 1:33 am
Becky,
Other patients are trying to tell you that if you do Ipi (Yervoy) first, and doesn't produce an immune response, then it may disqualify you from doing PD-1 or PD-L1 therapies.
Each trial have their own exclusion criteria. If you think you might want to do PD-1 therapy, you have to do it before Ipi. Ipi is now a FDA approved Drug here in the States. PD-1 on the other hand is still in clinical trials.
Example of exclusion criteria for a PD-1 trial
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T-cell costimulation pathways)
What I am trying to say is choose your therapy wisely.
-
- You must be logged in to reply to this topic.